BTIG cuts Connect Biopharma stock price target on trial timeline
BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.
How this was made
The 30-second read
Why it matters
Analyst target cuts reflect concerns over trial miss in acute asthma and cash runway, likely pressuring the stock.
Market read
The new target and trial data provide fresh actionable information for traders holding or considering CNTB.
What to watch
Potential FDA engagement and longer‑term pipeline could mitigate short‑term downside.
Background
Connect Biopharma reported mixed Phase II results for its rademikibart program, prompting analyst revisions.
Ticker impact
BTIG lowered Connect Biopharma's price target to $5 from $10 after mixed trial results, indicating reduced upside.
downward pressure as the market prices in the lower target and cash‑burn concerns
Target reduction reflects doubts on registrational success and cash runway, likely prompting sell pressure.
Market effects
Biotech sector may see heightened scrutiny on respiratory‑drug trials.
US biotech investors could adjust exposure to early‑stage respiratory assets.
Limited to niche biotech investors; no broad market effect.
Counterpoint
Some investors may view the trial's primary endpoint success as a catalyst for upside despite the target cut.
Key entities
- companyConnect Biopharma Holdings Ltd
Biopharma developer of rademikibart.
- analystBTIG
Equity research firm that lowered the price target.
